Wegovy 1.7 mg solution for injection in pre-filled pen

DRUG5 trials

Sponsors

Region Hovedstaden, Novo Nordisk A/S, Rigshospitalet, Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali

Conditions

Cannabis dependence (Cannabis Use Disorder or CUD)Cardiovascular diseaseDiabetes MellitusIdiopathic Intracranial HypertensionNon-alcoholic steatohepatitis (NASH)Obesity (BMI≥30kg/m2)Obesity and Heart Failure with reduced Ejection FracitionOverweight (BMI ≥27 kg/m²)

Phase 2

FIT-HF - Effect of weight loss on physical and cardiac performance in patients with heart failure and obesity

RecruitingCTIS2023-503753-35-01

Region HovedstadenObesity and Heart Failure with reduced Ejection Fracition

Start: 2024-03-20Target: 100Updated: 2025-08-22

A randomized, double-blind, placebo-controlled trial of semaglutide for reducing cannabis use in adults with cannabis use disorder

Not yet recruitingCTIS2025-524163-21-00

Region HovedstadenCannabis dependence (Cannabis Use Disorder or CUD)

Target: 100Updated: 2026-03-30

Phase 3

The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis

Active, not recruitingCTIS2023-506962-30-00

Novo Nordisk A/SNon-alcoholic steatohepatitis (NASH)

Start: 2021-03-29Target: 219Updated: 2025-11-11

Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study

Not yet recruitingCTIS2025-522486-29-01

Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco PasqualiCardiovascular disease, Diabetes Mellitus, Obesity (BMI≥30kg/m2) +1

Target: 212Updated: 2026-04-23

Phase 4

Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension

CompletedCTIS2024-517120-19-02

RigshospitaletIdiopathic Intracranial Hypertension

Start: 2022-09-02End: 2025-10-28Target: 50Updated: 2025-06-04